Who may participate
This study is seeking healthy male and female participants.
Participants must be healthy, meaning they will not have the condition for which this treatment is being developed and are in overall good health.
You may not take part in this study if:
- You are a woman of childbearing potential
- Japanese participants only: you do not have 4 biological Japanese grandparents who were born in Japan.
There are other requirements for participation in this study.
Please read attentively the Informed Consent Document (ICD), more explanation will be provided by the study staff during the screening process.
Condition
Healthy
Age
18 to 65
Sex
Male/female without childbearing potential
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in Brussels, Belgium.
The study will last for about 16 weeks. In this study you will have some tests, procedures, and assessments done.
The study doctor may also ask you to have extra tests, if needed, to protect your health.
- A screening examination.
- You will stay in the PCRU for 1 treatment period, comprised of 17 days and 16 nights (from Day -1 - to Day 16).
You will be screened within 28 days prior to the first dose of study intervention.
Throughout the study, staff will closely monitor your health status and collect data.
You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.
How long is the study?
Approximately 10 weeks
Compensation
Up to € 5.000, plus travel fees